Just been digging into the pharmaceutical space and there's something pretty interesting happening right now with GLP-1 drugs that's worth paying attention to.

So basically these GLP-1 medications started as diabetes treatments, but they've turned into absolute blockbusters for weight loss. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are already massive, and the anti-obesity drug market is projected to hit $100 billion in the next few years. That's the kind of scale that moves markets.

But here's what caught my eye: Pfizer just made a major play in this space. They acquired Metsera for $4.9 billion to get into the weight loss game. The interesting part? One of Metsera's candidates, MET-233i, can be dosed less frequently than the existing options and showed some solid efficacy — patients saw about 8.4% body weight loss in just 36 days during trials. That's a meaningful differentiator.

What's really happening here is that GLP-1 drugs are expanding beyond just obesity treatment. There's growing evidence they could help with alcohol cravings, opioid dependency, and even behavioral issues like gambling. So the addressable market is potentially even bigger than the obesity space alone.

If you're looking at best pharma stocks to buy now, this GLP-1 expansion is definitely one of the major tailwinds to consider. We've got Novo Nordisk and Eli Lilly as established players, but Pfizer entering the market with a potentially better formulation adds another layer to watch. The best pharma stocks to buy now are increasingly those positioned in this space.

The way I see it, as this trend accelerates over the next few years, the companies that can deliver superior efficacy or convenience could see significant upside. Worth keeping on your radar if you're thinking about pharmaceutical exposure.